Sofgen Pharma (PRCWF) director Carlos Garcia Iragorri files Form 3 with no reported trades

Rhea-AI Filing Summary

Sofgen Pharma S.A. filed an initial ownership report for director Carlos Garcia Iragorri. This Form 3 shows his status as a director of the company but does not list any share transactions or derivative positions. The summarized data indicate no reported purchases, sales, exercises, gifts, or other changes in ownership at this time.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Garcia Iragorri Carlos

(Last) (First) (Middle)

11600 MIRAMAR PARKWAY, SUITE 300

(Street)

MIRAMAR FLORIDA 33025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Sofgen Pharma S.A. [ PROC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

See Exhibit 24 - Power of Attorney.

No securities are beneficially owned.

	/s/ Freddy Andres Lozano Reyes, attorney-in-fact	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Sofgen Pharma (PRCWF) Form 3 filing report for Carlos Garcia Iragorri?

The Form 3 for Sofgen Pharma reports that Carlos Garcia Iragorri is a director and serves as a reporting person. The summary shows no reported share transactions, holdings entries, or derivative positions in this initial ownership statement.

Does the Sofgen Pharma (PRCWF) Form 3 show any share purchases or sales?

No, the Form 3 transaction summary shows zero buy and sell counts and zero net buy or sell shares. It indicates there were no reported purchases, sales, or other ownership-changing transactions included in this filing.

Is Carlos Garcia Iragorri a ten percent owner of Sofgen Pharma (PRCWF) according to the Form 3?

No, the Form 3 data mark the ten percent owner field as not applicable for Carlos Garcia Iragorri. He is identified as a director, but not as a ten percent owner in this initial ownership report.

Are any derivative securities reported for Sofgen Pharma (PRCWF) in this Form 3?

No derivative securities are listed in the filing, as the derivative summary is empty and the derivative transaction count is zero. This indicates no options, warrants, or other derivatives are reported in this Form 3.

What does a zero net buy/sell direction mean in the Sofgen Pharma (PRCWF) Form 3?

The Form 3 shows a net buy/sell direction of neutral with net buy or sell shares at zero. This means there were no reported ownership-increasing or ownership-decreasing transactions in the period covered by this initial statement.